Aehr Test Systems (AEHR) Stock: Why It Rose 21% After Q1 Results

Quick answer

Aehr Test Systems traded at $62.56 at 9:46am ET on Nov 3, 2026, up 21.5% from a $51.47 close, after it reported record revenue for its fiscal first quarter and raised its outlook. Revenue was $33.0 million, up 200% from $11.0 million a year earlier and 75% above the prior quarter, against roughly $27.5 million expected by analysts. Bookings were $46.7 million, effective backlog reached $109.3 million, and the company raised its fiscal 2027 revenue outlook to $150 million. The numbers came after the close on Nov 2, and the shares were already up 14% in extended trading that evening.

Our view: Bullish through January 8, 2027, the estimated date of the fiscal second-quarter report; the company has not set a date. The case against is real. The top of the outlook did not move, because $150 million was already the top of the old $130 million to $150 million range. Cash fell $11.4 million in the quarter and operating cash flow was negative. The stock trades at about 14 times the full-year revenue outlook, 18% of the float is sold short, and the 21.5% gain came on a day when chip equipment peers rose 4.6% to 9.9%. The lead hyperscale customer still drives much of the business, and the Taiwan production decision is months away. The case for the stock carries more weight. Effective backlog of $109.3 million equals 93% of the $117 million of revenue the outlook still needs for the rest of the year, bookings ran 1.4 times revenue, the company beat the revenue estimate by about 20% and lifted the low end of its outlook, and the stock sits 58% below its 52-week high after a slide from $107.21 on Oct 2 to $51.47. A move back above $33 million of quarterly revenue with bookings still above it in January would confirm the path. We would move off Bullish if second-quarter bookings fall below second-quarter revenue, if non-GAAP gross margin drops below 40% against 48.5% now, or if the Taiwan test cell installation slips past the first half of calendar 2027. This is a view on direction over that window, not a recommendation to trade the stock.

Aehr Test Systems daily closing price from Sep 21 to Nov 3, 2026, with the Oct 6 drop, the Nov 2 close and the Nov 3 gain marked

Key takeaways

Aehr Test Systems traded at $62.56 at 9:46am ET on Nov 3, 2026, up 21.5% from a $51.47 close, after it reported record first-quarter revenue of $33.0 million, up 200% from a year earlier, and raised its fiscal 2027 revenue outlook to $150 million.
Revenue beat the roughly $27.5 million analysts expected by about 20%, bookings were $46.7 million, a book-to-bill ratio of 1.4, and effective backlog reached $109.3 million as of Nov 1.
Chip equipment peers rose too, FormFactor 9.9%, Cohu 8.5% and Onto Innovation 8.2% at 9:46am, so part of the gain is a sector bid, but Aehr's gain was more than double any of them.
The stock is still 58% below its 52-week high of $147.40 and 18% of its float is sold short; cash fell $11.4 million in the quarter to $105.1 million.
Our view is Bullish through January 8, 2027, the estimated date of the second-quarter report: backlog covers 93% of the revenue still to ship this year, while the main risk is that the $150 million outlook leaves the top of the range unchanged.

Table of contents

Nov 3, 2026: a premarket gap, a sharp dip at the open and a push to a new session high
What the numbers say
The bull case
The risks
What comes next

Nov 3, 2026: a premarket gap, a sharp dip at the open and a push to a new session high

Aehr closed at $51.47 on Nov 2, down 6.2% on the day for its third straight drop. After the close it posted results, and by 6:55pm the shares traded at $58.80. Premarket trading on Nov 3 ranged from $56.48 to $62.33, with the high at 9:10am. The stock opened at $57.14, fell to $54.01 within the first five minutes, then reversed. It reached $63.44 by 9:40am and was $62.56 at 9:46am, up 21.5%, on 2.0 million shares.

The move is a recovery as much as a breakout. The shares have traded between $50 and $66 since Oct 22, and the $62.56 price sits near where they traded on Oct 29, before two weak sessions into the report. After the move, RSI(14) stood at 43, the shares sat 24% below their 50-day average and 16% below their 200-day average, and volume ran 0.7 times its 20-day average with the session still young. They remain 58% below the 52-week high of $147.40.

What happened:

A record quarter. Revenue of $33.0 million compares with $18.8 million in the quarter ended May 29 and $11.0 million a year earlier. Non-GAAP gross margin was 48.5%, up from 37.5%, on higher volume and product mix. Non-GAAP net income was $9.4 million, or $0.28 a share, against $0.2 million, or $0.01, a year earlier.
Orders ran ahead of sales. Bookings of $46.7 million were more than four times the $11.4 million of a year earlier, a book-to-bill ratio of about 1.4. Backlog was $100.9 million at quarter end, up from $80.6 million at the end of fiscal 2026, and $8.4 million of orders arrived after the quarter closed.
The outlook went up at the bottom. Fiscal 2027 revenue is now about $150 million, three times fiscal 2026. Non-GAAP net income is expected to be at least 20% of revenue, unchanged.
A new large evaluation. A major supplier of AI accelerators, CPUs and network processors finished a benchmark and is buying a fully configured FOX-XP wafer-level test cell for an outsourced assembly and test partner in Taiwan, with installation planned for early calendar 2027 and a production decision expected several months after validation. CEO Gayn Erickson called it among the company's largest potential opportunities.
The sector helped. FormFactor rose 9.9%, Cohu 8.5%, Onto Innovation 8.2% and Teradyne 4.6% at 9:46am. The semiconductor ETF SOXX rose 3.6% and Nvidia 3.1%, against 0.8% for the Nasdaq 100 fund QQQ. We found no news that explains the peers' gains.

Chart of Aehr Test Systems quarterly revenue against the Q1 estimate

What the numbers say

The revenue beat is large for a company this size, but the mix matters more than the headline. Consumables, meaning contactors, WaferPaks, burn-in modules and boards, were $13.5 million, or 41% of revenue, against $2.6 million, or 24%, a year earlier. These parts are used up as wafers are tested, so they come back as repeat orders, and management expects them to reach about 35% of fiscal 2027 revenue, up from 29% in fiscal 2026.

The outlook needs less than the first quarter suggests. A $150 million year after $33.0 million leaves $117 million for the last three quarters, about $39 million a quarter. That is only 18% above the first quarter's pace. CFO Chris Siu expects another strong second quarter on shipments to the lead hyperscale customer, and expects full-year gross margin near the first-quarter range, though the second quarter could be lower because of the Sonoma shipment mix. Erickson said revenue should rise over the remaining quarters but that order timing and shipment schedules can vary. For how outlook changes move stocks, see our guide to guidance changes.

Capacity is moving too. Sonoma shipments have started from an existing contract manufacturing site in Southeast Asia, adding room for more than 20 more systems a month, and Aehr signed a lease in Hsinchu, Taiwan. The company is debt-free, and appointed Vijay Rao, a technology executive with about 30 years of experience in hyperscale data centers, AI accelerators, memory and optical networking, to its board.

The bull case

Backlog covers the year. Effective backlog of $109.3 million against $117 million still to ship leaves little to find from new orders, even allowing that some orders ship after June 2027.
Customers are broadening. Management counts more than a dozen potential production customers across AI processors, silicon photonics, silicon carbide and gallium nitride, and added two gallium nitride production customers in six months.
The second AI processor is larger. The lead hyperscale customer's second processor passed Sonoma qualification, and the customer expects higher volumes than for the first, with a ramp expected in calendar 2027.
Estimates were low. The first-quarter estimate of $27.5 million was beaten by $5.5 million, and results like this tend to pull estimate revisions upward. The consensus price target is $132.50, with a range of $110 to $175, against a $62.56 stock.
The base is low. The shares are 58% below the high, and a fall in the stock before the report meant less had to go right.

The risks

Customer concentration. A handful of accounts still drive revenue, and growth depends on turning benchmarks into production orders. Qualification delays would push revenue out.
Cash. Cash and restricted cash fell to $105.1 million from $116.5 million at May 29, and operating cash flow was negative $3.1 million, mostly for working capital and long-lead parts for expected AI demand.
Valuation. The stock trades at about 41 times trailing sales and 9 times book value. On the $150 million outlook it is near 14 times sales, so the price needs the outlook to be met. See our explainer on price to sales.
Margins. The second quarter could see a lower gross margin as Sonoma systems, which carry a different mix, ship in volume.
Short interest and volatility. With 18% of the float short, a squeeze can lift the price quickly and fade just as fast. The stock fell 11.7% on Oct 6 and 6.2% on Nov 2.
Sector dependence. If chip equipment stocks give back their gains, Aehr's move is likely to give back some too.

Chart of the change in Aehr and related stocks and funds from the Nov 2 close to 9:46am ET on Nov 3

What comes next

The next dated test is the fiscal second-quarter report. A calendar estimate puts it on January 8, 2027, but Aehr has not announced a date. Watch bookings against the $33.0 million of first-quarter revenue, the gross margin against the 48.5% first-quarter level, and any update on the Taiwan test cell. Aehr also files its quarterly report with the SEC, which will give the first full cash flow and customer concentration detail. To read a release like this one, see how to read an earnings release, and for the call, how to analyze an earnings call transcript. More of today's biggest stock moves are on our market page, and our published work is in the research archive.

Frequently asked questions

Why is Aehr Test Systems stock up today?

Aehr traded at $62.56 at 9:46am ET on Nov 3, 2026, up 21.5% from a $51.47 close. After the close on Nov 2 it reported fiscal first-quarter revenue of $33.0 million, up 200% from $11.0 million a year earlier, and raised its fiscal 2027 revenue outlook to $150 million from a range of $130 million to $150 million. Bookings of $46.7 million were 1.4 times revenue.

What did Aehr report for the first quarter of fiscal 2027?

Revenue was $33.0 million, up 75% from $18.8 million in the prior quarter. Non-GAAP gross margin was 48.5%, non-GAAP net income was $9.4 million, or $0.28 a share, and GAAP net income was $7.2 million, or $0.21 a share. The quarter ended Sept 25, 2026.

What is Aehr Test Systems' fiscal 2027 guidance?

Aehr now expects fiscal 2027 revenue of about $150 million, three times fiscal 2026, and non-GAAP net income of at least 20% of revenue. The prior revenue range was $130 million to $150 million, so the low end rose and the top did not. The fiscal year ends June 25, 2027.

What does Aehr Test Systems make?

Aehr makes burn-in and test systems that run chips under heat and electrical stress to find early failures. Its FOX-XP systems test whole wafers and its Sonoma systems test packaged parts. Management says demand now comes from AI processors, silicon photonics, silicon carbide and gallium nitride.

How many customers does Aehr have?

Management said potential production customers now number more than a dozen. Growth still leans on a lead AI processor customer, which placed a $22 million follow-on order in August, and a lead hyperscale customer buying Sonoma systems, with more than a dozen shipped and installed each month. A new Taiwan evaluation could add a third large account.

Is Aehr Test Systems stock still below its high?

Yes. The 52-week high is $147.40 and the stock traded at $62.56 at 9:46am, about 58% below it. It closed at $51.47 on Nov 2, down from $107.21 on Oct 2, so the Nov 3 gain recovers only part of a one-month slide.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published November 3, 2026 · 7 min read · Event-Driven Investing